Su-Leng Tan Lee
Not independent
Tenure on this board
New nominee
4 nominees · 4 ballot items.
The four matters before stockholders are: election of four directors, approval of the 2025 Equity Incentive Plan, ratification of the independent registered public accounting firm, and, if necessary, an adjournment to solicit additional proxies.
Nomination of four current directors to serve on the board until the next annual meeting; four nominees named.
Approval of the BioNexus Gene Lab Corp. 2025 Equity Incentive Plan to grant equity awards, including stock options and restricted stock, with evergreen increases.
Ratification of JP Centurion & Partners PLT as the company’s independent registered public accounting firm for 2025; although not required, ratification is sought as good governance.
Approval of adjourning the meeting to solicit additional proxies if there are not sufficient votes for Proposal 2.
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | UBS Group AG | 0.01% | 231 | $495 |
| 2 | WELLS FARGO COMPANY/MN | 0.00% | 1 | $2 |
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.